A generic alternative indicated for Neurology. Mechanism of action modulates neurotransmitter signaling to facilitate the management of chronic pain sensitivity and physical discomfort.
Indicated to manage chronic pain from fibromyalgia by addressing neurotransmitter signals to support physical comfort and alleviate widespread sensitivity in adult patients.
Mechanism of Action
Milnacipran increases the activity of serotonin and norepinephrine in the brain and spinal cord. In fibromyalgia, these chemicals help to regulate and dampen pain signals, providing relief from chronic sensitivity.
Route of Administration
Oral
Onset Time
Steady state in 2 days; pain relief in weeks
Duration
12 hours
Contraindications
Concurrent MAOI use, Uncontrolled narrow-angle glaucoma, Hypersensitivity to milnacipran, Severe kidney disease
Severe Adverse Events
Serotonin syndrome, Suicidal thoughts or behavior, Hypertensive crisis, Liver toxicity, Seizures, Severe bleeding
Common Side Effects
Nausea, Dry mouth, Constipation
Uncommon Side Effects
Headache, Insomnia, Dizziness, Increased sweating, Palpitations, Hot flashes
Information for Savella is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
